N-Acetylcysteine Use to Prevent Contrast Medium-induced Nephropathy: Premature Phase III Trials

David A. Stenstrom; Leslie L. Muldoon; Hector Armijo-Medina; Suzanne Watnick; Nancy D. Doolittle; John A. Kaufman; Darryl R. Peterson; Joseph Bubalo; Edward A. Neuwelt

doi:10.1016/j.jvir.2007.11.003

N-Acetylcysteine Use to Prevent Contrast Medium-induced Nephropathy: Premature Phase III Trials

David A. Stenstrom, Leslie L. Muldoon, Hector Armijo-Medina, Suzanne Watnick, Nancy D. Doolittle, John A. Kaufman, Darryl R. Peterson, Joseph Bubalo, Edward A. Neuwelt

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

To date there has been no general consensus regarding the effectiveness of N-acetylcysteine as a protective therapy against contrast medium-induced nephropathy. Several phase III clinical trials have been conducted without a proper understanding of N-acetylcysteine pharmacology, particularly with regard to first-pass hepatic metabolism. A review was conducted of the literature concerning contrast medium-induced nephropathy and new studies of human N-acetylcysteine pharmacology were performed. After an analysis was performed, it was concluded that further phase I and phase II trials are needed. The efficacy of N-acetylcysteine in the prevention of contrast medium-induced nephropathy may be demonstrated with the use of higher doses than used in earlier studies, in combination with parenteral administration.

Original language	English (US)
Pages (from-to)	309-318
Number of pages	10
Journal	Journal of Vascular and Interventional Radiology
Volume	19
Issue number	3
DOIs	https://doi.org/10.1016/j.jvir.2007.11.003
State	Published - Mar 2008

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jvir.2007.11.003

Fingerprint Dive into the research topics of 'N-Acetylcysteine Use to Prevent Contrast Medium-induced Nephropathy: Premature Phase III Trials'. Together they form a unique fingerprint.

Cite this

N-Acetylcysteine Use to Prevent Contrast Medium-induced Nephropathy : Premature Phase III Trials. / Stenstrom, David A.; Muldoon, Leslie L.; Armijo-Medina, Hector; Watnick, Suzanne; Doolittle, Nancy D.; Kaufman, John A.; Peterson, Darryl R.; Bubalo, Joseph; Neuwelt, Edward A.

In: Journal of Vascular and Interventional Radiology, Vol. 19, No. 3, 03.2008, p. 309-318.

Research output: Contribution to journal › Review article › peer-review

Stenstrom, David A. ; Muldoon, Leslie L. ; Armijo-Medina, Hector ; Watnick, Suzanne ; Doolittle, Nancy D. ; Kaufman, John A. ; Peterson, Darryl R. ; Bubalo, Joseph ; Neuwelt, Edward A. / N-Acetylcysteine Use to Prevent Contrast Medium-induced Nephropathy : Premature Phase III Trials. In: Journal of Vascular and Interventional Radiology. 2008 ; Vol. 19, No. 3. pp. 309-318.

@article{012adc8f8a3a49aa8132aa1d35f2259a,

title = "N-Acetylcysteine Use to Prevent Contrast Medium-induced Nephropathy: Premature Phase III Trials",

abstract = "To date there has been no general consensus regarding the effectiveness of N-acetylcysteine as a protective therapy against contrast medium-induced nephropathy. Several phase III clinical trials have been conducted without a proper understanding of N-acetylcysteine pharmacology, particularly with regard to first-pass hepatic metabolism. A review was conducted of the literature concerning contrast medium-induced nephropathy and new studies of human N-acetylcysteine pharmacology were performed. After an analysis was performed, it was concluded that further phase I and phase II trials are needed. The efficacy of N-acetylcysteine in the prevention of contrast medium-induced nephropathy may be demonstrated with the use of higher doses than used in earlier studies, in combination with parenteral administration.",

author = "Stenstrom, {David A.} and Muldoon, {Leslie L.} and Hector Armijo-Medina and Suzanne Watnick and Doolittle, {Nancy D.} and Kaufman, {John A.} and Peterson, {Darryl R.} and Joseph Bubalo and Neuwelt, {Edward A.}",

year = "2008",

month = mar,

doi = "10.1016/j.jvir.2007.11.003",

language = "English (US)",

volume = "19",

pages = "309--318",

journal = "Journal of Vascular and Interventional Radiology",

issn = "1051-0443",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - N-Acetylcysteine Use to Prevent Contrast Medium-induced Nephropathy

T2 - Premature Phase III Trials

AU - Stenstrom, David A.

AU - Muldoon, Leslie L.

AU - Armijo-Medina, Hector

AU - Watnick, Suzanne

AU - Doolittle, Nancy D.

AU - Kaufman, John A.

AU - Peterson, Darryl R.

AU - Bubalo, Joseph

AU - Neuwelt, Edward A.

PY - 2008/3

Y1 - 2008/3

N2 - To date there has been no general consensus regarding the effectiveness of N-acetylcysteine as a protective therapy against contrast medium-induced nephropathy. Several phase III clinical trials have been conducted without a proper understanding of N-acetylcysteine pharmacology, particularly with regard to first-pass hepatic metabolism. A review was conducted of the literature concerning contrast medium-induced nephropathy and new studies of human N-acetylcysteine pharmacology were performed. After an analysis was performed, it was concluded that further phase I and phase II trials are needed. The efficacy of N-acetylcysteine in the prevention of contrast medium-induced nephropathy may be demonstrated with the use of higher doses than used in earlier studies, in combination with parenteral administration.

AB - To date there has been no general consensus regarding the effectiveness of N-acetylcysteine as a protective therapy against contrast medium-induced nephropathy. Several phase III clinical trials have been conducted without a proper understanding of N-acetylcysteine pharmacology, particularly with regard to first-pass hepatic metabolism. A review was conducted of the literature concerning contrast medium-induced nephropathy and new studies of human N-acetylcysteine pharmacology were performed. After an analysis was performed, it was concluded that further phase I and phase II trials are needed. The efficacy of N-acetylcysteine in the prevention of contrast medium-induced nephropathy may be demonstrated with the use of higher doses than used in earlier studies, in combination with parenteral administration.

UR - http://www.scopus.com/inward/record.url?scp=39449083331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449083331&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2007.11.003

DO - 10.1016/j.jvir.2007.11.003

M3 - Review article

C2 - 18295688

AN - SCOPUS:39449083331

VL - 19

SP - 309

EP - 318

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 3

ER -